Daiichi Sankyo Company, Limited

Subaru Corporation

Kobe Gakuin Educational Foundation

Mitsuhiro Iwamoto

Shinji Ashida

Narihiro Toda

Takeshi Masuda

Kensuke Nakamura

Hiroaki Uchida

Takashi Nakada

Yusuke Ota

Ichiro Hayakawa

Daisuke Okajima

Hirofumi Hamada

Tomoko Terauchi

Masaki Meguro

Fuminao Doi

Naoya Harada

Yukiko Sekiguchi

Takeshi Honda

Takahiro Katagiri

Rieko Takano

Takeshi Shida

Mami Yamazaki

Takahiro Yamaguchi

Makoto Koizumi

Kentaro Ito

Keiji Saito

Yoshiyuki Onishi

Masafumi Matsuo

Takahiro Nagayama

Yutaka Mori

Shinnosuke Tsuji

Hiroyuki Chaya

Yoshirou Kawaguchi

Shohei Oishi

Ryuki Miyauchi

The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate

Provided are novel antibody-pyrrolodiazepine derivative and novel antibody-pyrrolodiazepine derivative conjugates, as well as methods of using the same, and a novel CLDN6 and/or CLDN9 antibody. The disclosed compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics, and include substituted benzo[e]pyrrolo[1,2-α][1,4]diazepine.

Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines

The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82to the 92nucleotide from the 5′ end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).

Therapeutic agent for glycogen storage disease type IA

A vehicle body front structure includes front frames, first and second bumper beams, sub-frames, gussets, and load transmission members. The front frames extend in a front-rear direction. The first bumper beam is disposed in front of the front frames. The first bumper beam extends in a vehicle width direction. The sub-frames are disposed below the front frames. The sub-frames extend in the front-rear direction. The second bumper beam is coupled to front ends of the sub-frames. Ends of the second bumper beam protrude further outward than the first bumper beam. Each gusset is coupled to a corresponding one of ends of the second bumper beam and a corresponding one of intermediate portions of the sub-frames. The gussets transmit an impact load to the intermediate portions. The load transmission members are coupled to the sub-frames. The load transmission members are disposed on outer side surfaces of the front frame.

Vehicle body front structure

A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].

Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-&#x3b1;][1,4]diazepines

Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor

The present invention provides a conjugate comprising a hANP peptide bonded via a polyethylene glycol linker to a glycan attached to Asn297 of a Fc-containing molecule (N297 glycan), or a pharmaceutically acceptable salt thereof, a medicament comprising the same as an active ingredient, a method for producing the same, etc.

HANP-Fc-containing molecular conjugate

The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.

Endos mutant enzyme

The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

Glyco-modified atrial natriuretic peptide

To find a therapeutic and/or prophylactic agent for gastrointestinal disorders and so on, the agent having excellent activity and high safety. A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents an optionally substituted phenylene group; B represents an optionally substituted 4- to 10-membered heterocyclic group, an optionally substituted C6-C10 aryl group, or an optionally substituted C3-C10 cycloalkyl group; Rrepresents a hydrogen atom or a C1-C3 alkyl group; Rrepresents a hydrogen atom or a C1-C3 alkyl group; Rrepresents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C3 alkoxy C1-C3 alkyl group, or a C1-C3 hydroxyalkyl group; Rrepresents a hydrogen atom, a C1-C6 alkyl group, or a halogen atom; n represents an integer of 1 to 4; and X represents methylene, &#x2014;O&#x2014;, &#x2014;NH&#x2014;, &#x2014;N(C1-C3 alkyl)-, &#x2014;C(&#x2550;O)&#x2014;, &#x2014;S&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;S(O)&#x2014;, or a single bond. 

Piperazinyl cyclohexane compounds as GPR38 agonists

Piperazinyl methyl phenyl cyclohexane compound

Growing community of inventors

Tokyo, Japan

Mitsuhiro Iwamoto